PaulGrenaDOFACC

Cardiology • Yardley, PA

Nuclear Cardiology, Non-Invasive Cardiology, Preventive Cardiology

Partner, Cardiology Consultants of Philadelphia

Join to view full profile

Dr. Grena is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Grena's full profile

Already have an account?

Office
301 Oxford Valley Road
Suite 900
Yardley, PA 19067
Phone+1 215-321-7400
Is this information wrong?

Summary

Dr. Paul Grena is a Board certified cardiologist in Yardley, PA and is affiliated with Jefferson University Hospital and St. Mary Medical Center. He received his medical degree from Rowan University School of Osteopathic Medicine and has been in practice 29 years. He specializes in adult heart disease, nuclear cardiology and cardiovascular research.

Education & Training

Drexel University College of Medicine/Hahnemann University HospitalFellowship, Cardiovascular Disease, 1989 - 1995
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1989 - 1992
Rowan University School of Osteopathic MedicineClass of 1988

Certifications & Licensure

PA State License 1989 - 2024
PA State License 1991 - 2024
NJ State License 1991 - 2003
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

Phi Beta Kappa
Alpha Omega Alpha
Blockley Osler teaching award
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Fellow (FACC) American College of Cardiology
Join now to see all

Clinical Trials

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia Start of enrollment: 2006 May 01
Completed
Phase 2
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes Start of enrollment: 2020 May 29
Active, not recruiting
Phase 3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD Start of enrollment: 2019 Dec 12
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Bud...> ;Circulation. 2021-10-28
Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.
Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Frederich R, Maldonado M, Liu CC, Liu J, Pong A, Cannon CP, VERTIS CV Investigators> ;Clinical journal of the American Society of Nephrology : CJASN. 2021-06-18
Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection ...
Mitchell GF, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, Abbas CA, Desai AS, EVALUATE-HF Investigators*> ;Circulation. Heart failure. 2021-03-05
1 citations
Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry
George Ntaios, Menno V. Huisman, Hans-Christoph Diener, Jonathan L. Halperin, Christine Teutsch, Sabrina Marler, Venkatesh K. Gurusamy, Milla Thompson, Gregory Y.H. Li...> ;Hellenic Journal of Cardiology. 2021 Mar 1
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, Insalaco A, LeWinter M, Lewis BS, Lin D, Luis SA, Nicholls SJ, Pano A, Wheeler A, Paolini JF, RHAPSODY Inves...> ;The New England journal of medicine. 2020-11-16
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGu...> ;The New England journal of medicine. 2020-09-23
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AF.
Steinberg BA, Holmes DN, Pieper K, Allen LA, Chan PS, Ezekowitz MD, Freeman JV, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer ...> ;Circulation. Arrhythmia and electrophysiology. 2020-04-16
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile ...> ;The New England journal of medicine. 2019-09-01
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D...> ;The New England journal of medicine. 2019-09-01
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-...
Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenk...> ;Lancet (London, England). 2019-09-01
Join now to see all